Search Results 321-330 of 19189 for prostate cancer
Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. Prostate Cancer Prostatic Dis. 2021 ...
This therapy is an option for some people with neuroendocrine tumors, prostate cancer, meningiomas, thyroid cancer and lymphoma. It has proved to be ...
... prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease. Participation eligibility.
A Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer (CASCARA). Print details. Share; Facebook ...
... prostate cancer. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...
The study also seeks to further characterize (as possible) any other serious adverse reaction(s) in the long-term in adults with prostate cancer who received at ...
... prostate gland, which is also known as benign prostatic hyperplasia (BPH). ... prostate cancer. Make sure you tell all of your doctors that you are using ...
The purpose of this study is to evaluate the safety and tolerability of DCC-3014 in patients with solid tumors including, but not limited to, prostate, breast, ...
Prostate Cancer Screening Perception, Beliefs, and Practices Among Men in Bamenda, Cameroon Am J Mens Health. 2018. Odedina FT, Reams RR, Kaninjing E, Nguyen J, ...
For the study, "Adjuvant Hormonal Therapy Does Not Adversely Impact Overall Survival Following Radical Prostatectomy for Men with High Risk Prostate Cancer When ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your GivingTuesday gift can go 2X as far.